Author:
Ishige Fumitaka,Hoshino Isamu,Iwatate Yosuke,Chiba Satoshi,Arimitsu Hidehito,Yanagibashi Hiroo,Nagase Hiroki,Takayama Wataru
Abstract
AbstractPancreatic cancer is an aggressive tumor associated with poor survival, and early detection is important to improve patient outcomes. In the present study, we examined MIR1246 expression as a biomarker of pancreatic cancer. Total RNA was extracted from serum, urine and saliva samples from healthy subjects (n = 30) and patients with pancreatic cancer (n = 41, stage 0–IV). The MIR1246 level in each fluid was analyzed by quantitative reverse transcription-polymerase chain reaction. Significantly higher MIR1246 expression in serum and urine was observed in patients with cancer than in healthy controls. A significant positive correlation was found between serum and urine MIR1246 expression (r = 0.34). Receiver operating characteristic curves were constructed for MIR1246 in all three body fluids. The area under the curve for serum MIR1246 was 0.87 (sensitivity, 92.3%; specificity, 73.3%), and that for urine MIR1246 was 0.90 (sensitivity, 90.2%; specificity, 83.3%). With a cut-off of the control group’s mean plus twice the standard deviation, the sensitivities of MIR1246 in serum and urine for pancreatic cancer were 60.9 and 58.5%, respectively. Combining both serum and urine MIR1246 expression yielded a sensitivity of 85%. These results indicate that MIR246 may be a useful diagnostic biomarker for pancreatic cancer.
Publisher
Springer Science and Business Media LLC
Reference41 articles.
1. NATIONAL CANCER INSTITUTE-SEER Stat Fact Sheets: Pancreas Cancer. http://seer.cancer.gov/statfacts/html/pancreas.html. Accessed on 20th April, (2019).
2. Porta, M. et al. Exocrine pancreatic cancer: symptoms at presentation and their relation to tumour site and stage. Clin. Transl. Oncol. 7, 189–197 (2005).
3. Satake, K. et al. A clinical evaluation of various tumor markers for the diagnosis of pancreatic cancer. Int. J. Pancreatol. 7, 25–36 (1990).
4. Nazli, O., Bozdag, A. D., Tansug, T., Kir, R. & Kaymak, E. The diagnostic importance of CEA and CA 19-9 for the early diagnosis of pancreatic carcinoma. Hepatogastroenterology. 47, 1750–1752 (2000).
5. Sawabu, N., Watanabe, H., Yamaguchi, Y., Ohtsubo, K. & Motoo, Y. Serum tumor markers and molecular biological diagnosis in pancreatic cancer. Pancreas. 28, 263–267 (2004).
Cited by
29 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献